Oral fluoroquinolones (FQs) or other antibiotics are commonly used as antibacterial prophylaxis after cytotoxic chemotherapy for malignant neoplasms, although significant practice variations have been reported among centers and countries. 1 Despite such practical variations, the efficacy of oral FQ as a prophylactic agent has not been fully evaluated in the SCT setting. 2, 3 Further, the widespread emergence of multidrug-resistant microorganisms in hematology-oncology units has also increased the need for re-evaluating the role of antibacterial prophylaxis administered to patients undergoing cytotoxic chemotherapy or SCT. [4] [5] [6] [7] [8] [9] In attempts to reduce the emergence of antibiotic-resistant bacterial organisms, since 2003, we have discontinued the administration of oral FQs as prophylactic agents for patients undergoing standard-dose chemotherapy other than SCT; further, since 2004, we have withdrawn the use of any antibacterial prophylaxis in autoand allo-SCT recipients as well. 6 In allogeneic SCT after myeloablative conditioning regimens, the risk of bacterial infection is considerably high because high-dose chemotherapy and/or TBI may cause severe mucosal damage that facilitates bacterial translocation under profound post transplant immunosuppression. Therefore, we conducted a single-center retrospective study to evaluate the effect of such restriction of FQ prophylaxis on the incidence of bacterial infection and early mortality rate among patients receiving allo-SCT after myeloablative conditioning for hematologic malignancies.
The medical records were reviewed with respect to data on 145 consecutive adult patients with hematologic malignancies who underwent allogeneic myeloablative SCT with the use of T-cell-replete marrow or peripheral blood graft between January 2000 and December 2008 at our institution. Patients who had repeated episodes of bacterial infections, and those who had active infections before transplantation procedure were excluded; a total of 128 patients with the median age of 41.5 years (range, 17-61 years) were included in the analysis. Between January 2000 and August 2004, the patients received oral FQs (levofloxacin, tosufloxacin or ciprofloxacin) as antibacterial prophylactic agents (prophylaxis group). Patients who could not ingest oral drugs were temporarily administered anti-pseudomonal -lactams i.v. instead. From September 2004 to December 2008, the use of any prophylactic antibacterial agents, including oral FQs, was discontinued (non-prophylaxis group). In both groups, i.v. antibiotics with anti-pseudomonal activity were promptly administered in the episodes of febrile neutropenia or suspected bacterial infections.
There were no differences in patient characteristics between the prophylaxis and non-prophylaxis groups (Table 1) , except with regard to the preferential use of G-CSF in the prophylaxis group, which conferred significantly earlier neutrophil engraftment as compared with the non-prophylaxis group (median day, 15 (range, 10-67) in the prophylaxis group and 19.5 (12-30), in the nonprophylaxis group, Po0.001). During the entire study period, a total of 12 episodes of bacterial infections were documented; these included 11 cases of bloodstream infections and a single case of pneumonia. All organisms detected in the prophylaxis group were resistant to FQs; most of these organisms were gram-positive cocci (n ¼ 4, 67%). On the other hand, four of the six organisms detected in the non-prophylaxis group were FQ-sensitive gram-negative bacilli. Organ failure and septic shock because of bacterial infection were not observed, except in one patient in the prophylaxis group who succumbed to infection with metallo-b-lactamase-producing multidrugresistant Pseudomonas aeruginosa. In both groups, microbiologically documented infections developed during the early period after SCT (median day, 5.5 (range, 2-11) in the prophylaxis group and median day, 6.5 (1-13) in the non-prophylaxis group), and there was no statistically significant difference between the two groups in this regard (P ¼ 0.750). Although the cumulative incidence of microbiologically documented infections was slightly higher in the non-prophylaxis group (15%; 95% confidence interval (CI), 6-27%) than in the prophylaxis group (7%; 95% CI, 3%-13%), multivariate Cox analysis revealed this difference was not statistically significant (hazard ratio for the non-prophylaxis group vs prophylaxis group, 1.69; 95% CI, 0.40-7.08; P ¼ 0.473). The overall survival rates at 100 days after transplantation in the prophylaxis group and non-prophylaxis group were 89% (95% CI, 80-94%) and 90% (95% CI, 76-96%), respectively, with no significant difference between the groups in multivariate Cox analysis (P ¼ 0.682) (Figure 1) .
The emergence of multidrug-resistant microorganisms is becoming a serious problem in clinical settings in which SCT and cytotoxic chemotherapy are performed. Fre`re et al. 5 studied the drug susceptibility of bacterial organisms isolated from 492 patients who underwent auto-or allo-SCT between 1982 and 1999. They reported that the susceptibility to ciprofloxacin among gram-positive and gram-negative bacterial isolates was more than 70% in 1990, while it was o30% in 1997-1998; this observation suggested that FQ prophylaxis might no longer promise its clinical benefit at least in SCT settings. Given the increasing prevalence of FQ-resistant microorganisms, trials involving neutropenic patients with hematologic malignancies have been conducted to evaluate the effects of withdrawal of FQs as prophylactic agents. It is noteworthy that these studies showed that the susceptibility of enterobacterial isolates to FQ was significantly restored after FQ prophylaxis was discontinued. 6, 9 In addition, routine administration of FQs can induce cross-resistance to other antibiotics, such as b-lactams, through various mechanisms. 10 Therefore, the routine use of antibacterial prophylaxis in patients undergoing SCT should be carefully re-evaluated to reduce the prevalence of multidrug-resistant microorganisms.
Our present findings suggested that withdrawal of FQ as antibacterial prophylaxis is feasible without significant increase in the early mortality rate in allogeneic T-cellreplete BM or peripheral blood SCT after myeloablative conditioning, provided appropriate antibiotic treatment is promptly initiated in the event of febrile neutropenia. However, the retrospective study design, the heterogeneous underlying diseases in the small number of patients involved, and the variability in transplantation procedures used may have caused a bias in the results. Therefore, larger well-controlled prospective studies are needed to evaluate the role of antibacterial prophylaxis in BM or peripheral blood SCT after myeloablative conditioning. In addition, the significance of antibacterial prophylaxis in other SCT settings such as cord blood transplantation or SCT after reduced-intensity conditioning is also worth evaluating in the future study.
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